{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T02:15:01Z","timestamp":1768443301617,"version":"3.49.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T00:00:00Z","timestamp":1750032000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T00:00:00Z","timestamp":1750032000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s12185-025-04017-w","type":"journal-article","created":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T01:32:24Z","timestamp":1750037544000},"page":"199-205","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Distinct impact of letermovir discontinuation on tacrolimus pharmacokinetics based on concomitant azole antifungal agent"],"prefix":"10.1007","volume":"122","author":[{"given":"Sotaro","family":"Goto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daichi","family":"Sadato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7436-972X","authenticated-orcid":false,"given":"Takashi","family":"Toya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koki","family":"Narita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuho","family":"Najima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiko","family":"Yamamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriko","family":"Doki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,16]]},"reference":[{"issue":"20","key":"4017_CR1","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1182\/blood-2015-11-679639","volume":"127","author":"P Teira","year":"2016","unstructured":"Teira P, Battiwalla M, Ramanathan M, Barrett AJ, Ahn KW, Chen M, et al. Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis. Blood. 2016;127(20):2427\u201338.","journal-title":"Blood"},{"issue":"25","key":"4017_CR2","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","volume":"377","author":"FM Marty","year":"2017","unstructured":"Marty FM, Ljungman P, Chemaly RF, Maertens J, Dadwal SS, Duarte RF, et al. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med. 2017;377(25):2433\u201344.","journal-title":"N Engl J Med"},{"issue":"7","key":"4017_CR3","doi-asserted-by":"publisher","first-page":"371.e1","DOI":"10.1016\/j.jtct.2022.03.028","volume":"28","author":"KA Marciano","year":"2022","unstructured":"Marciano KA, Seago K, Dillaman M, Ross KG, Veltri L, Cumpston A. Evaluation of the pharmacokinetic interaction between letermovir and tacrolimus in allogeneic hematopoietic cell transplantation recipients. Transpl Cell Ther. 2022;28(7):371.e1-e4.","journal-title":"Transpl Cell Ther"},{"issue":"6","key":"4017_CR4","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1007\/s12185-021-03105-x","volume":"113","author":"T Nakashima","year":"2021","unstructured":"Nakashima T, Inamoto Y, Fukushi Y, Doke Y, Hashimoto H, Fukuda T, et al. Drug interaction between letermovir and voriconazole after allogeneic hematopoietic cell transplantation. Int J Hematol. 2021;113(6):872\u20136.","journal-title":"Int J Hematol"},{"issue":"2","key":"4017_CR5","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1007\/s12185-021-03277-6","volume":"115","author":"T Nakashima","year":"2022","unstructured":"Nakashima T, Inamoto Y, Aoki J, Ito A, Tanaka T, Kim SW, et al. Differences in kinetics of tacrolimus concentration after letermovir discontinuation by type of concomitant azole antifungal. Int J Hematol. 2022;115(2):158\u201362.","journal-title":"Int J Hematol"},{"issue":"7","key":"4017_CR6","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1002\/jcph.1094","volume":"58","author":"WL Marshall","year":"2018","unstructured":"Marshall WL, McCrea JB, Macha S, Menzel K, Liu F, van Schanke A, et al. Pharmacokinetics and tolerability of letermovir coadministered with azole antifungals (posaconazole or voriconazole) in healthy subjects. J Clin Pharmacol. 2018;58(7):897\u2013904.","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"4017_CR7","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transpl. 2013;48(3):452\u20138.","journal-title":"Bone Marrow Transpl"},{"issue":"7","key":"4017_CR8","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1177\/10781552221139772","volume":"29","author":"J Malespini","year":"2023","unstructured":"Malespini J, Lei M, Tavares E, Hammond SP, Chen YB, Luk SO, et al. Letermovir and tacrolimus interaction effects in hematopoietic cell transplantation recipients receiving moderate cytochrome P450 3A4 inhibitors for antifungal prophylaxis. J Oncol Pharm Pract. 2023;29(7):1574\u20139.","journal-title":"J Oncol Pharm Pract"},{"issue":"7","key":"4017_CR9","doi-asserted-by":"publisher","first-page":"859","DOI":"10.7150\/ijms.42011","volume":"17","author":"S Hikasa","year":"2020","unstructured":"Hikasa S, Shimabukuro S, Osugi Y, Ikegame K, Kaida K, Fukunaga K, et al. Tacrolimus concentration after letermovir initiation in hematopoietic stem cell transplantation recipients receiving voriconazole: a retrospective. Obs Study Int J Med Sci. 2020;17(7):859\u201364.","journal-title":"Obs Study Int J Med Sci"},{"issue":"7","key":"4017_CR10","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1111\/bcp.15677","volume":"89","author":"JB McCrea","year":"2023","unstructured":"McCrea JB, Menzel K, Fancourt C, Witter R, Zhao T, Robbins JA, et al. Evaluation of the inhibitory effects of itraconazole on letermovir. Br J Clin Pharmacol. 2023;89(7):2122\u201330.","journal-title":"Br J Clin Pharmacol"},{"issue":"Suppl 1","key":"4017_CR11","doi-asserted-by":"publisher","first-page":"i12","DOI":"10.1093\/ndt\/gfg1029","volume":"18","author":"NA Undre","year":"2003","unstructured":"Undre NA. Pharmacokinetics of tacrolimus-based combination therapies. Nephrol Dial Transpl. 2003;18(Suppl 1):i12\u20135.","journal-title":"Nephrol Dial Transpl"},{"issue":"1","key":"4017_CR12","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1002\/cpdd.1043","volume":"11","author":"J Scheuenpflug","year":"2022","unstructured":"Scheuenpflug J, Kropeit D, Erb-Zohar K, Theis JGW, Stobernack HP, McCormick D, et al. The effect of oral letermovir administration on the pharmacokinetics of a single oral dose of P-glycoprotein substrate digoxin in healthy volunteers. Clin Pharmacol Drug Dev. 2022;11(1):6\u201315.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"7","key":"4017_CR13","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1177\/1078155218801055","volume":"25","author":"AC Shumaker","year":"2019","unstructured":"Shumaker AC, Bullard HM, Churpek J, Knoebel RW. Posaconazole-digoxin drug-drug interaction mediated by inhibition of P-glycoprotein. J Oncol Pharm Pract. 2019;25(7):1758\u201361.","journal-title":"J Oncol Pharm Pract"},{"issue":"Suppl 1","key":"4017_CR14","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1046\/j.1365-2125.2003.01998.x","volume":"56","author":"L Purkins","year":"2003","unstructured":"Purkins L, Wood N, Kleinermans D, Nichols D. Voriconazole does not affect the steady-state pharmacokinetics of digoxin. Br J Clin Pharmacol. 2003;56(Suppl 1):45\u201350.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"4017_CR15","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1128\/AAC.46.1.160-165.2002","volume":"46","author":"EJ Wang","year":"2002","unstructured":"Wang EJ, Lew K, Casciano CN, Clement RP, Johnson WW. Interaction of common azole antifungals with P glycoprotein. Antimicrob Agents Chemother. 2002;46(1):160\u20135.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"4017_CR16","first-page":"511","volume":"82","author":"KT Olkkola","year":"1996","unstructured":"Olkkola KT, Ahonen J, Neuvonen PJ. The effects of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Anesth Analg. 1996;82(3):511\u20136.","journal-title":"Anesth Analg"},{"issue":"4","key":"4017_CR17","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.clpt.2005.12.305","volume":"79","author":"TI Saari","year":"2006","unstructured":"Saari TI, Laine K, Leino K, Valtonen M, Neuvonen PJ, Olkkola KT. Effect of voriconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Clin Pharmacol Ther. 2006;79(4):362\u201370.","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"4017_CR18","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.ejps.2004.01.005","volume":"21","author":"D Wexler","year":"2004","unstructured":"Wexler D, Courtney R, Richards W, Banfield C, Lim J, Laughlin M. Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study. Eur J Pharm Sci. 2004;21(5):645\u201353.","journal-title":"Eur J Pharm Sci"},{"issue":"1","key":"4017_CR19","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s12288-015-0506-5","volume":"32","author":"S Punatar","year":"2016","unstructured":"Punatar S, Gupta A, Gawande J, Bagal B, Mathew L, Kannan S, et al. Chronic graft versus host disease in acute leukemia patients undergoing allogeneic hematopoietic stem cell transplant: analysis of risk factors, pattern and long term outcome. Indian J Hematol Blood Transfus. 2016;32(1):32\u20138.","journal-title":"Indian J Hematol Blood Transfus"},{"issue":"4","key":"4017_CR20","doi-asserted-by":"publisher","first-page":"209.e1","DOI":"10.1016\/j.jtct.2021.12.020","volume":"28","author":"SI Kimura","year":"2022","unstructured":"Kimura SI, Kameda K, Harada K, Saburi M, Okinaka K, Shinohara A, et al. Risk and predictive factors for candidemia after allogeneic hematopoietic cell transplantation: JSTCT transplant complications working group. Transpl Cell Ther. 2022;28(4):209.e1-e9.","journal-title":"Transpl Cell Ther"},{"issue":"2","key":"4017_CR21","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1177\/0091270008327537","volume":"49","author":"J Weiss","year":"2009","unstructured":"Weiss J, Ten Hoevel MM, Burhenne J, Walter-Sack I, Hoffmann MM, Rengelshausen J, et al. CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole. J Clin Pharmacol. 2009;49(2):196\u2013204.","journal-title":"J Clin Pharmacol"},{"key":"4017_CR22","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02230-17","author":"HJ Suh","year":"2018","unstructured":"Suh HJ, Yoon SH, Yu KS, Cho JY, Park SI, Lee E, et al. The genetic polymorphism UGT1A4*3 is associated with low posaconazole plasma concentrations in hematological malignancy patients receiving the oral suspension. Antimicrob Agents Chemother.\u00a02018 Jun 26;62(7):e02230-17.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"4017_CR23","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1097\/FTD.0000000000001198","volume":"46","author":"M Sugimoto","year":"2024","unstructured":"Sugimoto M, Yonezawa A, Kanda J, Itohara K, Hira D, Yamagiwa T, et al. Population pharmacokinetic modeling of posaconazole in japanese patients receiving fungal prophylaxis. Ther Drug Monit. 2024;46(5):611\u20138.","journal-title":"Ther Drug Monit"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-04017-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-025-04017-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-04017-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T19:31:23Z","timestamp":1757187083000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-025-04017-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,16]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["4017"],"URL":"https:\/\/doi.org\/10.1007\/s12185-025-04017-w","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,16]]},"assertion":[{"value":"29 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Takashi Toya received grants from Japan Society for the Promotion of Science (24K11668), and received lecture fee from MSD K.K., Astellas Pharma, Daiichi-Sankyo, Asahi Kasei Pharma, and Meiji Seika Pharma. Y.N. received consulting fees from Astellas Pharma and Daiichi-Sankyo, and lecture fees from AbbVie, Astellas, Chugai Pharmaceutical, Daiichi Sankyo, JCR Pharma, MSD K.K., Novartis Pharma, Sumitomo Pharma, Amgen, Bristol-Myers Squibb, CSL Behring, Janssen Pharmaceutical, Kyowa Kirin, Nippon Shinyaku, Otsuka Pharmaceutical, Takeda Pharmaceutical, and Meiji Seika Pharma. N.D. received grants from Japan Agency for Medical Research and Development (24ek0510039h0003) and Japan Society for the Promotion of Science (23K06709), consulting fees from Janssen Pharmaceutical, and lecture fees from Nippon Shinyaku, Novartis Pharma, Daiichi-Sankyo, AstraZeneca, Otsuka Pharmaceutical, Asahi Kasei Pharma, Sanofi, Pfizer, Janssen Pharmaceutical, Kyowa Kirin, AbbVie, Astellas Pharma, Chugai Pharmaceutical, Shionogi & Co, Merck & Co, and Takeda Pharmaceutical. None of these are related to the current study. Other authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}